[1]THIAUCOURT F, BÖLSKE G, LENEGUERSSH B, et al. Diagnosis and control of contagious caprine pleuropneumonia[J]. Rev Sci Tech, 1996, 15(4): 1415-1429.
[2]TAM J P, LU Y A. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes[J]. Proc Natl Acad Sci U S A, 1989, 86(23): 9084-9088.
[3]FRANCIS M J, HASTINGS G Z, BROWN F, et al. Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus[J]. Immunology, 1991, 73(3): 249-254.
[4]NARDELI B, LU Y A, SHIU D R, et al. A chemically defined synthetic vaccine model for HIV-I[J]. J Immunol, 1992, 148(3): 914-920.
[5]PESSI A, VALMORI D, MIGLIORINI P, et al. Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide[J]. Eur J Immunol, 1991, 21(9): 2273-2276.
[6]AMEXIS G, YOUN N S. Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus[J]. Viral Immunol, 2007, 20(4): 657-663.
[7]GARCIA T C, FONSECA C T, PACIFICO L G, et al. Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice[J]. Acta Trop, 2008, 106(3): 162-167.
[8]DALLO S F, KANNAN T R, BLAYLOCK M W, et al. Elongation factor Tu and E1 beta subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae[J]. Mol Microbiol, 2002, 46(4): 1041-1051.
[9]DE BERARDINIS P , HAIGWOOD N L. New recombinant vaccines based on the use of prokaryotic antigen-display systems[J]. Expert Rev Vaccines, 2004, 3(6): 673-679.
[10]BURNETT T A, DINLIA K, ROHDE M, et al. P159 is a proteolytically processed, surface adhesin of Mycoplasma hyopneumoniae:defined domains of P159 bind heparin and promote adherence to eukaryote cells[J]. Mol Microbiol, 2006, 60(3): 669-686.
[11]ZHAO P, HE Y, CHU Y F, et al. Identification of novel immunogenic proteins in Mycoplasma capricolum subsp. capripneumoniae strain M1601[J]. J Vet Med Sci, 2012, 74(9):1109-1115.
[12]ZHAO P, HE Y, CHU Y F, et al. Optimizing and expressing of proteins including PDHA, PDHB and PDHC of Mycoplasma capricolum subsp. capripneumoniae[J]. Asian J Anim Vet Adv , 2013, 8(5): 723-731.
[13]CHU Y, GAO P, ZHAO P, et al. Genome sequence of the Mycoplasma capricolum subspecies capripneumoniae strain M1601[J]. J Bacteriol, 2011, 193(21):6098-6099.
[14]WAITE E R , MARCH J B. Capsular polysaccharide conjugate vaccines against contagious bovine pleuropneumonia: immune responses and protection in mice[J]. J Comp Pathol, 2002, 126 (2-3): 171-182.
[15]WANG Y, WANG M, WANG G, et al. Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens[J]. Vaccine, 2011, 29(47):8619-8623.
[16]CHATTERJEE S, SHARMA P, KUMAR S, et al. Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens[J]. Vaccine, 1995, 13(15):1461-1474.
[17]TAM J P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system[J]. Proc Natl Acad Sci U S A, 1988, 85(15): 5409-5413.
[18]LIVINGSTON B D, NEWMAN M, CRIMI C, et al. Optimization of epitope processing enhances immunogenicity of vaccines[J]. Vaccine, 2001, 19(32): 4652-4660.
[19]KHAN M A, OGITA K, FERRO V A, et al. Immunisation with a plasmid DNA vaccine encoding gonadotropin-releasing hormone(GnRH-I) and T-helper epitopes in saline suppresses rodent fertility[J]. Vaccine, 2008, 26(10): 1365-1374. |